中医药调控Keap1/Nrf2信号通路治疗肝癌的研究进展  

Research progress on traditional Chinese medicine and pharmacy regulating Keap1/Nrf2 signaling pathway in the treatment of liver cancer

作　　者：叶一娴 杜沅沁 赵雅然 彭倩 韦燕飞 YE Yixian;DU Yuanqing;ZHAO Yaran;PENG Qian;WEI Yanfei(Basic Medical College,Guangxi University of Chinese Medicine,Guangxi Zhuang Autonomous Region,Nanning530200,China;the First Clinical Medical College,Guangxi University of Chinese Medicine,Guangxi Zhuang Autonomous Region,Nanning530022,China)

机构地区：[1]广西中医药大学基础医学院,广西南宁530200 [2]广西中医药大学第一临床医学院,广西南宁530022

出　　处：《中国医药导报》2025年第9期51-54,共4页China Medical Herald

基　　金：国家自然科学基金资助项目(82260786)。

摘　　要：肝癌是全球常见的恶性肿瘤之一,发生率和死亡率居高不下。目前治疗肝癌的方法效果不佳,且有许多不良反应。Keap1/Nrf2信号通路是目前肝癌预防、诊断和治疗的研究热点。中医药通过调控Keap1/Nrf2信号通路治疗肝癌具有靶点多、副作用小、综合治疗等独特优势。本文对中医药通过Keap1/Nrf2信号通路治疗肝癌的研究进展进行综述,以期为中医药防治肝癌提供参考。Liver cancer is a prevalent malignant tumor globally with high incidence rate and mortality.The current methods in the treatment of liver cancer are ineffective,and have many adverse reactions.Keap1/Nrf2 signaling pathway is currently a research hotspot in the prevention,diagnosis,and treatment of liver cancer.Traditional Chinese medicine and pharmacy has unique advantages in the treatment of liver cancer by regulating Keap1/Nrf2 signaling pathway,including multiple targets,minimal side effects,and comprehensive treatment.This article reviews research progress on traditional Chinese medicine and pharmacy in the treatment of liver cancer through Keap1/Nrf2 signaling pathway,in order to provide reference for the prevention and treatment of liver cancer with t traditional Chinese medicine and pharmacy.

关 键 词：Keap1/Nrf2信号通路 中医药 肝癌 

分 类 号：R735.7[医药卫生—肿瘤]